Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

The ME/CFS Collaboration

at Uppsala University

State-of-the-art laboratory searching for biomarkers of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) in body and brain.

About the research center

Established in 2019, this research center is directed by Jonas Bergquist, MD, PhD. Prior to this new center, Dr. Bergquist had already been researching ME/CFS for nearly a decade. Dr. Bergquist and his lab develop novel methods for extracting patient samples and measuring the metabolites and proteins within those samples.

They then apply these methods to produce unique and valuable data from a range of diseases.  Along with ME/CFS, his lab has a general interest in neurodegenerative diseases such as Parkinson’s, Alzheimer’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

The ME/CFS CRC at Uppsala University is looking for ME/CFS biomarkers to develop a diagnostic test and to contribute to the understanding of what initiates the disease process.  Not only are they looking for single metabolites or proteins, they are looking for the pattern of all the data the extract from ME/CFS patient samples and are working towards a defining biochemical signature of the disease.

This collaborative research initiative is looking to develop methods to measure proteins, peptides and metabolites in the blood and cerebrospinal fluid of ME/CFS patients to help define the underlying biological cause, to form a diagnostic and to ultimately find treatments for the disease.

Core Aims

Understand

the underlying basis of neurological symptoms 

Determine

the role of neuroinflammation in ME/CFS

 

Compare

and contrast ME/CFS to other diseases

Find

biomarkers for ME/CFS in the blood and cerebrospinal fluid

Uncover

the role of autoantibodies and autonomic issues in ME/CFS

Begin

treatment trials of drugs that reduce the debilitating symptoms of ME/CFS

Uppsala-CRC-lab-cropped-scaled.jpeg

Fundamental Philosophy

  • Work collaboratively with groups around the world
  • Develop novel techniques to make biofluid sampling minimally invasive and harmful
  • Optimize the data detection platforms to enhance the search for biomarkers of disease
  • Spread knowledge of the disease far and wide
  • Follow research leads to their end to uncover and publish important findings
  • Bring young researchers into the ME/CFS field
  • Research multiple biofluids of the body

View our latest news

studies

Post-viral Encephalopathy

This study provides an excellent opportunity to understand the mechanism of long-lasting viral-induced cognitive complications, commonly referred to as “brain fog.”

Read More

Autoimmunity and Autoantibodies

The aim is to investigate potential differences in adrenergic and muscarinic receptor autoantibody levels in plasma and cerebrospinal fluid samples between ME/CFS patients and healthy controls.

Read More

Scientific Team

The large-scale research endeavors of the ME/CFS Collaborative Research Center at Uppsala University require a diverse team. Dr. Bergquist has assembled a great team of scientists and clinicians to fulfill their goals.

Uppsala University (Sweden)

Jonas Bergquist, MD, PhD, Prof, Director

Kumari Ubhayasekhera, PhD

Ganna Shevchenko, PhD

Levon Manukyan, PhD

Sandy Abujrais, PhD Student

Mark Dennis Retrato, PhD Student

Annie Bynke, Med Student

Hanna Gustafsson, Med Student

Torsten Gordh, MD, PhD, Prof em

 

Massachusetts General Hospital (Harvard)

Ronald Tompkins, MD, ScD

Wenzhong Xiao, PhD

 

Stanford University

Ronald Davis, PhD

 

Karolinska Institut (Sweden)

Per Julin, MD, PhD

Bragee Clinics Stockholm

Bo C. Bertilsson, MD, PhD

Björn Bragée, MD

Kent Nilsson, MD

Gunnar Olsson, MD, PhD, Ass. Prof

Jonas Axelsson, MD, PhD, Ass. Prof

Britt Bragée, RPT, PhD

Gabriella Bernhoff RPT, PhD Student

Brandon Drum, Med Student

Michael Fahlqvist, MD-internship

Michos Anastasios, MD

 

Gottfries clinic (Sweden)

CG Gottfries, MD, PhD, Prof em

 

Linkoping University (Sweden)

Anders Rosén, MD, PhD, Prof em

Björn Ingelsson,  PhD, Ass prof

Eirini Apostoulo, PhD, Post doc

Rizwan Muhammad, Guest Researcher

 

University of East Anglia (UK)

Simon Carding, PhD, Prof

SUPPORT OMF Funded Critical Research

Please help us expand our research efforts across the globe. Every donation brings us closer to a fully-funded research effort and the answers we all seek.

Learn about Our Other OMF Funded Collaborative Research Centers

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo